PTPN7

Summary

PTPN7 (protein tyrosine phosphatase non-receptor type 7, HGNC:9659) is a protein-coding gene on chromosome 1q32.1, encoding Tyrosine-protein phosphatase non-receptor type 7 (P35236). Protein phosphatase that acts preferentially on tyrosine-phosphorylated MAPK1.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This gene is preferentially expressed in a variety of hematopoietic cells, and is an early response gene in lymphokine stimulated cells. The non-catalytic N-terminus of this PTP can interact with MAP kinases and suppress the MAP kinase activities. This PTP was shown to be involved in the regulation of T cell antigen receptor (TCR) signaling, which was thought to function through dephosphorylating the molecules related to MAP kinase pathway. Multiple alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 5778 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 81 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002832

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9659
Approved symbol	PTPN7
Name	protein tyrosine phosphatase non-receptor type 7
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	HEPTP, LC-PTP
Ensembl gene	ENSG00000143851
Ensembl biotype	protein_coding
OMIM	176889
Entrez	5778

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 17 protein_coding, 4 nonsense_mediated_decay, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000309017, ENST00000367279, ENST00000435759, ENST00000462815, ENST00000464870, ENST00000467283, ENST00000468385, ENST00000476061, ENST00000477554, ENST00000477625, ENST00000479092, ENST00000480836, ENST00000486116, ENST00000491584, ENST00000492451, ENST00000492977, ENST00000495688, ENST00000496197, ENST00000629151, ENST00000691036, ENST00000854611, ENST00000854612, ENST00000854613, ENST00000854614, ENST00000854615

RefSeq mRNA: 5 — MANE Select: NM_002832 NM_001199797, NM_001364877, NM_001364878, NM_002832, NM_080588

CCDS: CCDS1422, CCDS1423

Canonical transcript exons

ENST00000691036 — 10 exons

Exon	Start	End
ENSE00001927044	202160545	202160602
ENSE00003519003	202157739	202157823
ENSE00003552765	202154186	202154323
ENSE00003581167	202155533	202155609
ENSE00003676719	202153725	202153835
ENSE00003685300	202152542	202152699
ENSE00003693260	202150311	202150424
ENSE00003790609	202158118	202158301
ENSE00003928474	202147016	202148699
ENSE00004282191	202159281	202159454

Expression profiles

Bgee: expression breadth ubiquitous, 185 present calls, max score 96.39.

FANTOM5 (CAGE): breadth broad, TPM avg 14.2904 / max 863.6909, expressed in 550 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16705	12.3266	529
16704	0.9593	187
16708	0.3261	106
16709	0.3165	110
16702	0.1913	109
16703	0.1089	27
16707	0.0292	10
16710	0.0165	6
16711	0.0104	4
16706	0.0056	1

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	96.39	gold quality
lymph node	UBERON:0000029	92.07	gold quality
bone marrow cell	CL:0002092	90.77	gold quality
vermiform appendix	UBERON:0001154	90.06	gold quality
thymus	UBERON:0002370	88.84	gold quality
blood	UBERON:0000178	88.26	gold quality
spleen	UBERON:0002106	88.11	gold quality
adrenal tissue	UBERON:0018303	86.99	gold quality
bone marrow	UBERON:0002371	84.84	gold quality
right testis	UBERON:0004534	84.71	gold quality
caecum	UBERON:0001153	84.37	gold quality
left testis	UBERON:0004533	84.10	gold quality
putamen	UBERON:0001874	83.67	gold quality
right adrenal gland cortex	UBERON:0035827	81.98	gold quality
testis	UBERON:0000473	81.85	gold quality
leukocyte	CL:0000738	81.68	gold quality
caudate nucleus	UBERON:0001873	81.44	gold quality
gall bladder	UBERON:0002110	80.79	gold quality
small intestine Peyer’s patch	UBERON:0003454	80.72	gold quality
mononuclear cell	CL:0000842	80.60	gold quality
monocyte	CL:0000576	80.53	gold quality
ileal mucosa	UBERON:0000331	80.26	gold quality
left adrenal gland cortex	UBERON:0035825	79.83	gold quality
left adrenal gland	UBERON:0001234	79.45	gold quality
adrenal gland	UBERON:0002369	79.33	gold quality
right adrenal gland	UBERON:0001233	78.93	gold quality
tonsil	UBERON:0002372	78.90	gold quality
adrenal cortex	UBERON:0001235	78.68	gold quality
rectum	UBERON:0001052	78.51	gold quality
small intestine	UBERON:0002108	78.41	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-9467	yes	33.09
E-MTAB-10287	yes	29.19
E-CURD-112	yes	9.05
E-HCAD-10	yes	6.68
E-GEOD-70580	no	922.59
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

81 targeting PTPN7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-425-5P	99.59	67.67	900
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-4269	99.55	69.89	1373
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6081	99.48	66.07	1446

Literature-anchored findings (GeneRIF, showing 4)

• structure of the protein tyrosine phosphatase catalytic domain of HePTP, residues 44-339 (PMID:16226275)
• determined high-resolution structures of all of the human family members of Mitogen-Activated Protein Kinase-specific protein tyrosine phosphatases (PMID:16441242)
• Interactions at the active site between KIM (kinase interaction motif)-phosphatases and their substrates are predominantly nonspecific, with the majority of the KIM-phosphatase residues coordinating the peptide backbone rather than residue side chains. (PMID:19053285)
• PTPN7 regulates platelet functional responses downstream of GPCR agonists, but not GPVI agonists, through inhibition of ERK activation and thromboxane generation. (PMID:31266805)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ptpn7	ENSMUSG00000031506
rattus_norvegicus	Ptpn7	ENSRNOG00000005807

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRE (ENSG00000132334), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPRG (ENSG00000144724), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Protein

Protein identifiers

Tyrosine-protein phosphatase non-receptor type 7 — P35236 (reviewed: P35236)

Alternative names: Hematopoietic protein-tyrosine phosphatase, Protein-tyrosine phosphatase LC-PTP

All UniProt accessions (12): P35236, C9IYI6, C9JAW7, C9JBA9, E7EUM0, E9PE54, F8WEY3, F8WF08, F8WF66, H7C4T8, H7C5I3, J3KR55

UniProt curated annotations — full annotation on UniProt →

Function. Protein phosphatase that acts preferentially on tyrosine-phosphorylated MAPK1. Plays a role in the regulation of T and B-lymphocyte development and signal transduction.

Subunit / interactions. Monomer. Interacts with MAPK1, MAPK3 and several other MAP kinases.

Subcellular location. Cytoplasm. Cytoskeleton.

Tissue specificity. Expressed exclusively in thymus and spleen.

Post-translational modifications. Phosphorylated on serine residues in resting T-cells. Phosphorylation increases upon exposure to stimuli that increase intracellular cAMP levels. Phosphorylation leads to dissociation of bound MAP kinases. Oxidized at active site cysteine. Treatment with pervanadate (vanadate and H(2)O(2)) or with antigen enhanced oxidation of active site cysteine.

Activity regulation. Inhibited in cells after FCER1A triggering.

Similarity. Belongs to the protein-tyrosine phosphatase family. Non-receptor class subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
P35236-1	1	yes
P35236-2	2
P35236-3	3

RefSeq proteins (5): NP_001186726, NP_001351806, NP_001351807, NP_002823, NP_542155 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR008356	Tyr_Pase_KIM-con	Family
IPR016130	Tyr_Pase_AS	Active_site
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily

Pfam: PF00102

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (54 total): helix 14, strand 13, mutagenesis site 8, modified residue 6, sequence conflict 3, binding site 3, splice variant 2, region of interest 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

14 structures.

PDB	Method	Resolution (Å)
1ZC0	X-RAY DIFFRACTION	1.85
2GPH	X-RAY DIFFRACTION	1.9
3D44	X-RAY DIFFRACTION	1.9
3O4S	X-RAY DIFFRACTION	1.9
2QDC	X-RAY DIFFRACTION	2
2GP0	X-RAY DIFFRACTION	2.05
2QDM	X-RAY DIFFRACTION	2.05
8YP8	X-RAY DIFFRACTION	2.14
3O4U	X-RAY DIFFRACTION	2.25
2HVL	X-RAY DIFFRACTION	2.4
3D42	X-RAY DIFFRACTION	2.46
2A3K	X-RAY DIFFRACTION	2.55
3O4T	X-RAY DIFFRACTION	2.6
2QDP	X-RAY DIFFRACTION	2.72

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P35236-F1	86.39	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 291 (phosphocysteine intermediate)

Ligand- & substrate-binding residues (3): 257; 291–297; 335

Post-translational modifications (6): 93, 110, 143, 291, 44, 66

Mutagenesis-validated functional residues (8):

Position	Phenotype
44	prevents dissociation of bound map kinase and enhances their dephosphorylation.
44	reduces binding of map kinase.
66	prevents dissociation of bound map kinase and enhances their dephosphorylation; when associated with a-93.
93	prevents dissociation of bound map kinase and enhances their dephosphorylation; when associated with a-66.
125	strongly reduced catalytic activity.
257	loss of catalytic activity.
291	loss of catalytic activity.
335	reduced catalytic activity.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-5675221	Negative regulation of MAPK pathway
R-HSA-9008059	Interleukin-37 signaling

MSigDB gene sets: 169 (showing top): WALLACE_PROSTATE_CANCER_RACE_UP, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, KEGG_MAPK_SIGNALING_PATHWAY, MODULE_45, AP4_Q6, MODULE_16, ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN, MODULE_118, WEI_MYCN_TARGETS_WITH_E_BOX, AML_Q6, PID_TCR_RAS_PATHWAY, MODULE_213, ZHAN_V1_LATE_DIFFERENTIATION_GENES_DN, MARZEC_IL2_SIGNALING_UP, MAF_Q6

GO Biological Process (4): MAPK cascade (GO:0000165), protein dephosphorylation (GO:0006470), signal transduction (GO:0007165), dephosphorylation (GO:0016311)

GO Molecular Function (5): protein tyrosine phosphatase activity (GO:0004725), non-membrane spanning protein tyrosine phosphatase activity (GO:0004726), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (7): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), cytoplasmic side of plasma membrane (GO:0009898), microtubule cytoskeleton (GO:0015630), mitotic spindle (GO:0072686), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RAF/MAP kinase cascade	1
Interleukin-1 family signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular signaling cassette	1
dephosphorylation	1
protein modification process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
phosphate-containing compound metabolic process	1
phosphoprotein phosphatase activity	1
protein tyrosine phosphatase activity	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
plasma membrane	1
cytoplasmic side of membrane	1
cytoskeleton	1
spindle	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1266 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPN7	PTS	Q03393	923
PTPN7	MAPK1	P28482	919
PTPN7	MAPK14	Q16539	700
PTPN7	DUSP3	P51452	640
PTPN7	MAPK3	P27361	575
PTPN7	DUSP6	Q16828	558
PTPN7	MAP2K1	Q02750	537
PTPN7	RPS6KA1	Q15418	530
PTPN7	OSBP	P22059	520
PTPN7	RPS6KA3	P51812	516
PTPN7	PTPN11	Q06124	516
PTPN7	DUSP23	Q9BVJ7	488
PTPN7	PLPP1	O14494	472
PTPN7	ACP1	P24666	463
PTPN7	DUSP10	Q9Y6W6	461

IntAct

27 interactions, top by confidence:

A	B	Type	Score
PTPN7	MAPK1	psi-mi:“MI:0915”(physical association)	0.770
PTPN7	MAPK1	psi-mi:“MI:2364”(proximity)	0.770
PTPN7	MAPK1	psi-mi:“MI:0203”(dephosphorylation reaction)	0.770
PTPN7	Mapk14	psi-mi:“MI:0915”(physical association)	0.590
Mapk14	PTPN7	psi-mi:“MI:0915”(physical association)	0.590
PTPN7	CCDC57	psi-mi:“MI:0915”(physical association)	0.560
PTPN7	FLJ13057	psi-mi:“MI:0915”(physical association)	0.560
CCDC57	PTPN7	psi-mi:“MI:0915”(physical association)	0.560
FLJ13057	PTPN7	psi-mi:“MI:0915”(physical association)	0.560
Mapk1	PTPN7	psi-mi:“MI:0407”(direct interaction)	0.440
PTPN7	AATK	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	EGFR	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	ERBB3	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	ROR2	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	PTK7	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	EPHA2	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	ERBB4	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	IGF1R	psi-mi:“MI:0915”(physical association)	0.370
PTPN7	MAPK14	psi-mi:“MI:2364”(proximity)	0.270
PTPN7	CDH2	psi-mi:“MI:0203”(dephosphorylation reaction)	0.000

BioGRID (84): GMCL1 (Two-hybrid), CCDC57 (Two-hybrid), MAPK1 (Co-localization), MAPK14 (Co-localization), PTPN7 (Biochemical Activity), PTPN7 (Biochemical Activity), PTPN7 (Two-hybrid), PTPN7 (Two-hybrid), PTPN7 (Two-hybrid), DHPS (Affinity Capture-MS), MAPK1 (Affinity Capture-MS), MAPK14 (Affinity Capture-MS), MAPK3 (Affinity Capture-MS), ME1 (Affinity Capture-MS), OPA1 (Affinity Capture-MS)

ESM2 similar proteins: A2ALK8, A5D6R3, B2GV87, O08617, O35239, O55082, P0C599, P0C5A1, P18052, P18433, P23469, P25044, P26045, P28202, P28204, P28205, P28206, P28209, P28219, P29350, P29351, P35234, P35235, P35236, P41499, P43378, P49445, P49446, P54755, P54830, P81718, Q03348, Q06124, Q15256, Q4JDL3, Q4RQD3, Q5I127, Q5I139, Q5I141, Q5I142

Diamond homologs: A0A6I8TCE0, A1L1L3, A2ALK8, A4IFW2, B0V2N1, B0X4T2, B1AUH1, B2GV87, B2RU80, B3DK56, B9EKR1, E9Q0N2, E9Q612, F1NWE3, G5EC24, G5EGJ9, H2KZM6, O02695, O08617, O13016, O35239, O55082, P06800, P16620, P17706, P18031, P18052, P18433, P20417, P23467, P23468, P23469, P23470, P23471, P26045, P28191, P29074, P29350, P29351, P29352

SIGNOR signaling

22 interactions.

A	Effect	B	Mechanism
CD40LG	down-regulates	PTPN7
PRKACA	down-regulates	PTPN7	phosphorylation
PTPN7	down-regulates	MAPK14	binding
PTPN7	“down-regulates activity”	MAPK1	dephosphorylation
PTPN7	“down-regulates activity”	MAPK14	dephosphorylation
PRKCQ	“up-regulates activity”	PTPN7	phosphorylation
PTPN7	down-regulates	MAPK1	dephosphorylation
MAPK1	“up-regulates activity”	PTPN7	phosphorylation
MAPK3	“up-regulates activity”	PTPN7	phosphorylation
MAPK14	“down-regulates activity”	PTPN7	phosphorylation
Gbeta	“up-regulates activity”	PTPN7	phosphorylation
ERK1/2	“up-regulates activity”	PTPN7	phosphorylation
PRKD1	“up-regulates activity”	PTPN7	phosphorylation
PRKCZ	“up-regulates activity”	PTPN7	phosphorylation
PRKCD	“up-regulates activity”	PTPN7	phosphorylation
PRKCH	“up-regulates activity”	PTPN7	phosphorylation
PRKCE	“up-regulates activity”	PTPN7	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 15 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of MAPK cascade	5	33.6×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

81 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2071 predictions. Top by Δscore:

Variant	Effect	Δscore
1:202148696:CCCT:C	acceptor_gain	1.0000
1:202148697:CCT:C	acceptor_gain	1.0000
1:202148697:CCTC:C	acceptor_gain	1.0000
1:202148698:CT:C	acceptor_gain	1.0000
1:202148698:CTC:C	acceptor_gain	1.0000
1:202148699:TCTGC:T	acceptor_gain	1.0000
1:202152537:CGCA:C	donor_loss	1.0000
1:202152538:GCA:G	donor_loss	1.0000
1:202152539:CA:C	donor_loss	1.0000
1:202152540:ACCT:A	donor_loss	1.0000
1:202152696:GGTA:G	acceptor_gain	1.0000
1:202152697:GTA:G	acceptor_gain	1.0000
1:202152698:TA:T	acceptor_gain	1.0000
1:202152698:TAC:T	acceptor_loss	1.0000
1:202152700:C:CC	acceptor_gain	1.0000
1:202152701:T:A	acceptor_loss	1.0000
1:202152705:T:TC	acceptor_gain	1.0000
1:202153721:GTA:G	donor_loss	1.0000
1:202153722:TA:T	donor_loss	1.0000
1:202153723:ACCT:A	donor_loss	1.0000
1:202153831:CATTT:C	acceptor_gain	1.0000
1:202153832:ATTT:A	acceptor_gain	1.0000
1:202153833:TTT:T	acceptor_gain	1.0000
1:202153834:TT:T	acceptor_gain	1.0000
1:202153834:TTCTA:T	acceptor_loss	1.0000
1:202153835:TCTA:T	acceptor_loss	1.0000
1:202153836:C:A	acceptor_loss	1.0000
1:202153837:T:G	acceptor_loss	1.0000
1:202154184:ACCT:A	donor_gain	1.0000
1:202154185:CCTC:C	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000434821 (1:202162125 T>C), RS1000493902 (1:202158468 C>T), RS1000543952 (1:202153788 G>A), RS1000602285 (1:202152834 A>C), RS1001040410 (1:202163276 G>A), RS1001085084 (1:202147957 G>A,T), RS1001105306 (1:202147545 G>A), RS1001229189 (1:202150258 G>A), RS1001264429 (1:202148944 C>T), RS1001317357 (1:202160303 A>G,T), RS1001324290 (1:202156116 A>C), RS1001868389 (1:202159121 G>C), RS1002284043 (1:202157338 C>T), RS1002388356 (1:202151970 G>A), RS1002562499 (1:202163398 A>G)

Disease associations

OMIM: gene MIM:176889 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001930_15	Breast cancer	1.000000e-08
GCST90002380_117	Basophil percentage of white cells	5.000000e-10
GCST90002380_118	Basophil percentage of white cells	6.000000e-10
GCST90002397_789	Mean spheric corpuscular volume	3.000000e-12
GCST90002400_534	Plateletcrit	9.000000e-19

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007992	basophil percentage of leukocytes
EFO:0007985	platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2219 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 327,449 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1440	TETRACYCLINE	4	324,384
CHEMBL1632	CEPHALOTHIN SODIUM	4	3,065

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

316 measured of 520 human assays (581 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
MLS000116276	EC50	0.00207 nM
2-[[7-(2-furanylmethyl)-5,6-diphenyl-4-pyrrolo[2,3-d]pyrimidinyl]amino]ethanol	EC50	0.00424 nM
SMR000071260	EC50	15.5 nM
3-[2-(hydroximinomethyl)pyrrol-1-yl]benzoic acid	IC50	23 nM
4-chloranyl-N-(3,4-dihydro-2H-thiochromen-4-yl)-3-sulfamoyl-benzamide	IC50	121 nM
7-hexacosenoic acid	IC50	220 nM
4-amino-3-(4-methylphenyl)-5-[(4-methyl-1-piperazinyl)carbonyl]-1,3-thiazole-2(3H)-thione	IC50	250 nM
1-(2,6-dichlorophenyl)-3-(2-phenylethyl)thiourea	IC50	342 nM
4-[[2-bromanyl-4-[(E)-2-cyano-2-(3-fluorophenyl)ethenyl]phenoxy]methyl]benzoic acid	IC50	400 nM
2-[2-chloranyl-6-ethoxy-4-[(E)-[2-(naphthalen-2-ylamino)-4-oxidanylidene-1,3-thiazol-5-ylidene]methyl]phenoxy]ethanoic acid	IC50	440 nM
MLS-0054638.0001	IC50	478 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-(2-methoxyethyl)urea	IC50	492 nM
MLS000050448	IC50	716 nM
MLS-0109562.0001	IC50	727 nM
cid_6161440	IC50	730 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-(2-phenylethyl)urea	IC50	814 nM
Cephalothin	IC50	920 nM
2-[4-[(E)-[[4-[2-(4-chloroanilino)-1,3-thiazol-4-yl]benzoyl]hydrazinylidene]methyl]phenoxy]acetic acid	IC50	924 nM
3-[(5E)-5-[[4-[(4-chlorophenyl)methoxy]-3-methoxyphenyl]methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]benzoic acid	IC50	953 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-butylurea	IC50	966 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-phenylurea	IC50	968 nM
2-[4-[(Z)-[2-(4-fluoroanilino)-4-keto-2-thiazolin-5-ylidene]methyl]phenoxy]acetic acid methyl ester	IC50	1050 nM
2-[3-[2-hydroxyethyl(dimethyl)azaniumyl]propanoylamino]-2-methyl-propane-1-sulfonate	EC50	1160 nM
2-[2-chloranyl-6-methoxy-4-[(Z)-[3-[2-[(4-methylphenyl)amino]-2-oxidanylidene-ethyl]-2,4-bis(oxidanylidene)-1,3-thiazolidin-5-ylidene]methyl]phenoxy]ethanoic acid	IC50	1180 nM
2-[2,6-bis(chloranyl)-4-[(Z)-[3-[2-[(4-methylphenyl)amino]-2-oxidanylidene-ethyl]-2,4-bis(oxidanylidene)-1,3-thiazolidin-5-ylidene]methyl]phenoxy]ethanoic acid	IC50	1200 nM
(7Z)-3-bromanyl-7-(furan-2-ylmethylidene)-[1,3]thiazolo[4,5]imidazo[1,2-b]pyridin-8-one	IC50	1230 nM
3-(2-{(E)-[1-(4-chlorophenyl)-2,5-dioxoimidazolidin-4-ylidene]methyl}-1H-pyrrol-1-yl)benzoic acid	IC50	1230 nM
3-[(5E)-5-[1-(2-chlorobenzyl)-2-keto-indolin-3-ylidene]-4-keto-2-thioxo-thiazolidin-3-yl]propionic acid	IC50	1230 nM
2-[5-[(Z)-(3-bromanyl-8-oxidanylidene-[1,3]thiazolo[4,5]imidazo[1,2-b]pyridin-7-ylidene)methyl]furan-2-yl]benzoic acid	IC50	1250 nM
3-(3-chloranyl-4-methoxy-phenyl)-1-(3-methylbutyl)-1-(1-propan-2-ylpiperidin-4-yl)thiourea	IC50	1260 nM
4-[3-[(5Z)-4-keto-2-thioxo-5-veratrylidene-thiazolidin-3-yl]propanoylamino]benzoic acid	IC50	1270 nM
2-[4-[[[4-[2-(4-chloroanilino)-1,3-thiazol-4-yl]benzoyl]hydrazinylidene]methyl]phenoxy]acetic acid	IC50	1300 nM
3-[[2,3-bis(2-furyl)quinoxalin-6-yl]carbamoylamino]propionic acid ethyl ester	IC50	1420 nM
1-ethyl-6-methyl-3-[(E)-2-phenylethenyl]pyrimido[5,4-e][1,2,4]triazine-5,7-dione	EC50	1440 nM
cid_9595040	IC50	1490 nM
2-hydroxy-4-({4-[5-(2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]butanoyl}amino)benzoic acid	IC50	1560 nM
MLS-0202048.0001	IC50	1600 nM
1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione	EC50	1610 nM
4-keto-5-methyl-2-[(E)-2-(4-methyl-3-nitro-phenyl)vinyl]-3H-thieno[2,3-d]pyrimidine-6-carboxylic acid	IC50	1620 nM
9-octacosynoic acid	IC50	1760 nM
1,6-dimethyl-3-propyl-pyrimido[5,4-e][1,2,4]triazine-5,7-dione	EC50	1770 nM
MLS-0336006.0001	IC50	1830 nM
4-[[5-(4-bromophenyl)-2-furoyl]thiocarbamoylamino]benzoic acid	IC50	1880 nM
5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylic acid [2-[(1,1-diketothiolan-3-yl)-isobutyl-amino]-2-keto-ethyl] ester	IC50	1910 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-(1-naphthalenyl)urea	IC50	2040 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-(4-chlorophenyl)urea	IC50	2140 nM
2-(5,6-dihydro-4H-cyclopent[d]isoxazole-3-carbonylamino)benzoic acid methyl ester	IC50	2180 nM
N-[5-(1,3-benzothiazol-2-yl)-2-methylphenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide	IC50	2210 nM
1-[2,3-bis(2-furanyl)-6-quinoxalinyl]-3-methylurea	IC50	2300 nM
MLS000527911	IC50	2310 nM

ChEMBL bioactivities

315 potent at pChembl≥5 of 441 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.84	IC50	14.4	nM	CHEMBL1605172
7.60	IC50	25	nM	CHEMBL1322542
7.46	IC50	34.5	nM	CHEMBL1408579
7.23	IC50	58.6	nM	CHEMBL1304193
7.18	IC50	66	nM	CHEMBL1460470
7.07	IC50	84.6	nM	CHEMBL1608642
7.00	IC50	100	nM	CEFAMANDOLE SODIUM
6.98	IC50	105	nM	CHEMBL1445488
6.97	IC50	108	nM	CHEMBL1505246
6.90	IC50	125	nM	CHEMBL454668
6.90	IC50	127	nM	CHEMBL1603381
6.89	IC50	130	nM	CHEMBL4750435
6.89	IC50	129	nM	CHEMBL1407203
6.80	IC50	159	nM	CHEMBL1371869
6.75	IC50	180	nM	CHEMBL1448629
6.71	IC50	196	nM	CHEMBL1447397
6.71	IC50	193	nM	CHEMBL1701224
6.70	IC50	200	nM	CHEMBL492894
6.70	IC50	200	nM	CHEMBL1527520
6.70	IC50	198	nM	CHEMBL1501132
6.68	IC50	209	nM	CHEMBL1536896
6.64	IC50	227	nM	CHEMBL1393151
6.60	IC50	250	nM	CHEMBL454668
6.59	IC50	256	nM	CHEMBL1407368
6.55	IC50	280	nM	CHEMBL1334633
6.55	IC50	284	nM	CHEMBL1449836
6.55	IC50	280	nM	CHEMBL1526088
6.52	IC50	304	nM	CHEMBL1414679
6.51	IC50	312	nM	CHEMBL1438889
6.50	IC50	314	nM	CHEMBL1393151
6.48	IC50	329	nM	CHEMBL1371777
6.48	IC50	331	nM	CHEMBL1327648
6.46	IC50	343	nM	CHEMBL1390354
6.43	IC50	373	nM	CHEMBL1732016
6.41	IC50	391	nM	CHEMBL1414679
6.41	IC50	394	nM	CHEMBL1704862
6.40	IC50	400	nM	CHEMBL1539325
6.39	IC50	410	nM	CHEMBL1324051
6.39	IC50	410	nM	CHEMBL1376870
6.38	IC50	420	nM	CHEMBL1978364
6.38	IC50	420	nM	CHEMBL259355
6.38	IC50	419	nM	CHEMBL1424189
6.35	IC50	447	nM	CHEMBL1408579
6.35	IC50	450	nM	CHEMBL1715328
6.34	IC50	455	nM	CHEMBL1605172
6.34	IC50	452	nM	CHEMBL1702580
6.33	IC50	472	nM	CHEMBL1725599
6.33	IC50	466	nM	CHEMBL1732016
6.33	IC50	465	nM	CHEMBL1488869
6.32	IC50	483	nM	CHEMBL501993

PubChem BioAssay actives

32 with measured affinity, of 171 total; 30 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[4,5-bis(1,3,2-dithiarsolan-2-yl)-3-hydroxy-6-oxoxanthen-9-yl]benzoic acid	1495216: Inhibition of allosterically sensitized mutant form of His6-tagged human HePTP catalytic domain using pNPP as substrate incubated for 90 mins by quenched phosphatase activity assay	ic50	0.1250	uM
4-[1-(4-methoxyphenyl)-3-(2-oxochromen-7-yl)pyrrolo[2,3-b]pyridin-5-yl]benzoic acid	1706923: Inhibition of PTPN7 (unknown origin) pre-incubated for 20 mins followed by fluorescence substrate addition and measured after 120 mins by DiFMUP assay	ic50	0.1300	uM
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid	2037695: Inhibition of HEPTP (unknown origin) using pNPP as substrate by high-throughput screening assay	ic50	0.2000	uM
2-[(5Z)-5-[[3-[4-[(4-chlorophenyl)methoxy]phenyl]-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443925: Inhibition of recombinant HePTP	ic50	0.6200	uM
2-[4-[(Z)-[5-(4-chlorophenyl)-7-methyl-3-oxo-6-propan-2-yloxycarbonyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]acetic acid	569652: Competitive inhibition of recombinant HePTP expressed in Escherichia coli by Michaelis-Menten kinetic analysis	ki	0.6900	uM
2-[(5Z)-5-[[3-[4-[(2-fluorophenyl)methoxy]phenyl]-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443925: Inhibition of recombinant HePTP	ic50	0.8700	uM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	1182542: Inhibition of HePTP (unknown origin)	ic50	1.0300	uM
2-[(5Z)-5-[[3-[4-[(2-chlorophenyl)methoxy]phenyl]-1-phenylpyrazol-4-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443925: Inhibition of recombinant HePTP	ic50	1.2000	uM
2-[4-[(Z)-[5-(4-chlorophenyl)-6-ethoxycarbonyl-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]acetic acid	569641: Inhibition of recombinant HePTP expressed in Escherichia coli	ic50	1.3000	uM
2-[(5Z)-4-oxo-5-[[1-phenyl-3-(4-phenylmethoxyphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443925: Inhibition of recombinant HePTP	ic50	1.5000	uM
2-[4-[(Z)-[6-ethoxycarbonyl-7-methyl-5-(4-methylsulfanylphenyl)-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]acetic acid	569641: Inhibition of recombinant HePTP expressed in Escherichia coli	ic50	1.8000	uM
6-hydroxy-2-phenyl-3-[2-[4-(trifluoromethoxy)phenyl]ethynyl]-1-benzofuran-5-carboxylic acid	725030: Inhibition of HEPTP (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	1.9000	uM
6-hydroxy-2-phenyl-3-[2-[3-(trifluoromethyl)phenyl]ethynyl]-1-benzofuran-5-carboxylic acid	725030: Inhibition of HEPTP (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	2.1000	uM
2-[(5Z)-4-oxo-5-[[1-phenyl-3-(4-piperidin-1-ylsulfonylphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid	443925: Inhibition of recombinant HePTP	ic50	2.4000	uM
3-[2-(3-chlorophenyl)ethynyl]-6-hydroxy-2-[4-[2-oxo-2-(propylamino)ethoxy]phenyl]-1-benzofuran-5-carboxylic acid	755776: Inhibition of recombinant HEPTP (unknown origin) using pNPP as substrate by spectrophotometric analysis	ic50	3.0000	uM
3-[2-(3,5-difluorophenyl)ethynyl]-6-hydroxy-2-phenyl-1-benzofuran-5-carboxylic acid	725030: Inhibition of HEPTP (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis	ic50	3.3000	uM
3-[1-[4-[(4-chloronaphthalen-1-yl)amino]-4-oxobutyl]triazol-4-yl]-6-hydroxy-2-(4-methylphenyl)-1-benzofuran-5-carboxylic acid	566825: Inhibition of HePTP	ic50	3.6900	uM
6-hydroxy-2-(4-methoxyphenyl)-3-[1-[4-(naphthalen-1-ylamino)-4-oxobutyl]triazol-4-yl]-1-benzofuran-5-carboxylic acid	566825: Inhibition of HePTP	ic50	3.7000	uM
2-[4-[(Z)-[5-(2-chlorophenyl)-6-ethoxycarbonyl-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]-2-methoxy-6-methylphenoxy]acetic acid	569641: Inhibition of recombinant HePTP expressed in Escherichia coli	ic50	3.7000	uM
6-hydroxy-2-(4-methylphenyl)-3-[1-[4-(naphthalen-1-ylamino)-4-oxobutyl]triazol-4-yl]-1-benzofuran-5-carboxylic acid	566825: Inhibition of HePTP	ic50	4.0700	uM
2-[4-[(Z)-[6-ethoxycarbonyl-5-(3-methoxyphenyl)-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]acetic acid	569641: Inhibition of recombinant HePTP expressed in Escherichia coli	ic50	4.6000	uM
6-hydroxy-3-[1-[4-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-4-oxobutyl]triazol-4-yl]-2-(3-methylphenyl)-1-benzofuran-5-carboxylic acid	566825: Inhibition of HePTP	ic50	6.3600	uM
(2S)-2-[4-[4-(2-benzyl-1-benzofuran-3-yl)phenyl]phenoxy]-3-phenylpropanoic acid	1942820: Inhibition of HEPTP (unknown origin)	ic50	7.1000	uM
16221757	286242: Inhibition of HePTP	ic50	7.5000	uM
3-chloro-N-(5-methyl-1,3-benzothiazol-2-yl)-1-benzothiophene-2-carboxamide	695227: Inhibition of HePTP expressed in Escherichia coli BL21 using pNPP substrate	ic50	8.0000	uM
2-(3-cyano-7,8-dimethylquinolin-2-yl)sulfanyl-N-cyclohexylacetamide	695227: Inhibition of HePTP expressed in Escherichia coli BL21 using pNPP substrate	ic50	8.0000	uM
4-[1-(cyclohexylamino)-1-oxohexan-2-yl]oxy-2-hydroxy-5-[2-[2-(trifluoromethoxy)phenyl]ethynyl]benzoic acid	1206789: Inhibition of HePTP (unknown origin) using pNPP as substrate at pH 7 at 25 degC by spectrophotometric analysis	ic50	8.7000	uM
2-[(5,6-dimethyl-4-oxo-3H-thieno[2,3-d]pyrimidin-2-yl)sulfanyl]-N-(6-ethoxy-1,3-benzothiazol-2-yl)acetamide	695227: Inhibition of HePTP expressed in Escherichia coli BL21 using pNPP substrate	ic50	9.0000	uM
(5Z)-3-(3-chlorophenyl)-5-[(4-hydroxy-3-methoxy-5-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one	1799621: PTP Assay from Article 10.1002/cbic.200600287: “Cellular inhibition of protein tyrosine phosphatase 1B by uncharged thioxothiazolidinone derivatives.”	ic50	9.3000	uM
2-(3-cyano-5,8-dimethylquinolin-2-yl)sulfanyl-N-(2-ethyl-6-methylphenyl)acetamide	695227: Inhibition of HePTP expressed in Escherichia coli BL21 using pNPP substrate	ic50	10.0000	uM

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	2
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	decreases methylation	1
triphenyltin	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
Acetaminophen	increases expression	1
Benzene	increases expression	1
Catechin	affects cotreatment, decreases expression	1
Curcumin	increases expression	1
Diuron	decreases expression	1
Lead	increases expression	1
Methapyrilene	decreases methylation	1
Nickel	increases expression	1
Oxygen	decreases expression	1
Rotenone	increases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases methylation	1
Paclitaxel	increases expression	1
Antirheumatic Agents	decreases expression	1

ChEMBL screening assays

72 unique, capped per target: 63 binding, 8 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1047963	Binding	Inhibition of recombinant HePTP	Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. — J Med Chem
CHEMBL1613806	Functional	PUBCHEM_BIOASSAY: In Vitro HePTP Dose Response Colorimetric Assay for SAR Study. (Class of assay: confirmatory) [Related pubchem assays: 521 ]	PubChem BioAssay data set
CHEMBL4626299	ADMET	Inhibition of HePTP (unknown origin) expressed in Escherichia coli BL21 using p-nitrophenyl phosphate as substrate measured after 30 mins by UV-vis spectrophotometric method	Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.